A infecção cutânea por Mycobacterium kansasii envolve M. kansasii afetando a pele. Quando o isolado é sensível à rifampicina, as diretrizes atuais especificam uma abordagem antimicobacteriana multidrogas estruturada com objetivos terapêuticos definidos.
O manejo é centrado em um esquema antimicobacteriano multidrogas, com o curso de tratamento recomendado se estendendo por mais de 12 meses.
DOI: 10.3389/fphar.2023.1242156
According to the official ATS/ERS/ESCMID/IDSA clinical practice guidelines, for patients with rifampin-susceptible M. kansasii, a treatment course lasting over 12 months, comprising rifampicin, ethambutol, and either isoniazid or a macrolide, is advised.
These assessments typically involve evaluating the complete or substantial disappearance of preexisting skin lesions, the absence of new skin lesions, and the persistence of unchanged skin lesions after a specific duration of treatment.
Treatment outcome includes bacteriological negative conversion, bacteriological cure, clinical cure, cure, treatment failure, bacteriological recurrence, and death.
View source ↗